{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T06:32:05Z","timestamp":1794983525579,"version":"4.9.1"},"reference-count":25,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The International Prognostic Scoring System (IPSS) has been widely used to predict the prognosis of patients with myelodysplastic syndrome (MDS). However, IPSS does not always provide a sufficiently precise evaluation of patients to allow the appropriate choice of clinical interventions. Here, we analyzed the expression of Bmi-1, which is required to regulate the self-renewal in CD34+ cells from 51 patients with cases of MDS and acute myeloid leukemia preceded by MDS (MDS-AML). Higher positivity rate of Bmi-1 was preferentially seen in refractory anemia with excess blasts (RAEB), RAEB in transformation (RAEB-T), and MDS-AML compared with refractory anemia (RA) and RA with ringed sideroblasts (RARS). IPSS score was positively correlated with the percentage of Bmi-1 expression. Patients with RA and RARS with a higher percentage of Bmi-1+ cells showed disease progression to RAEB. Here, we propose Bmi-1 as a novel molecular marker to predict the progression and prognosis of MDS.<\/jats:p>","DOI":"10.1182\/blood-2005-06-2393","type":"journal-article","created":{"date-parts":[[2005,9,14]],"date-time":"2005-09-14T03:23:38Z","timestamp":1126668218000},"page":"305-308","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":111,"title":["Bmi-1 is useful as a novel molecular marker for predicting progression of myelodysplastic syndrome and patient prognosis"],"prefix":"10.1182","volume":"107","author":[{"given":"Keichiro","family":"Mihara","sequence":"first","affiliation":[{"name":"From the Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima; the Department of Internal Medicine, National Kure Medical Center, Kure; and the Department of Stem Cell Biology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moniruddin","family":"Chowdhury","sequence":"additional","affiliation":[{"name":"From the Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima; the Department of Internal Medicine, National Kure Medical Center, Kure; and the Department of Stem Cell Biology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanae","family":"Nakaju","sequence":"additional","affiliation":[{"name":"From the Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima; the Department of Internal Medicine, National Kure Medical Center, Kure; and the Department of Stem Cell Biology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiko","family":"Hidani","sequence":"additional","affiliation":[{"name":"From the Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima; the Department of Internal Medicine, National Kure Medical Center, Kure; and the Department of Stem Cell Biology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Ihara","sequence":"additional","affiliation":[{"name":"From the Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima; the Department of Internal Medicine, National Kure Medical Center, Kure; and the Department of Stem Cell Biology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Hyodo","sequence":"additional","affiliation":[{"name":"From the Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima; the Department of Internal Medicine, National Kure Medical Center, Kure; and the Department of Stem Cell Biology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin'ichiro","family":"Yasunaga","sequence":"additional","affiliation":[{"name":"From the Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima; the Department of Internal Medicine, National Kure Medical Center, Kure; and the Department of Stem Cell Biology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Takihara","sequence":"additional","affiliation":[{"name":"From the Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima; the Department of Internal Medicine, National Kure Medical Center, Kure; and the Department of Stem Cell Biology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiro","family":"Kimura","sequence":"additional","affiliation":[{"name":"From the Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima; the Department of Internal Medicine, National Kure Medical Center, Kure; and the Department of Stem Cell Biology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111704503707100_REF1","doi-asserted-by":"crossref","unstructured":"Heaney ML, Golde DW. Myelodysplasia. N Engl J Med. 1999;340; 1649-1660.","DOI":"10.1056\/NEJM199905273402107"},{"key":"2019111704503707100_REF2","doi-asserted-by":"crossref","unstructured":"Lowenthal RM, Marsden KA. Myelodysplastic syndromes. Int J Hematol. 1997;65: 319-338.","DOI":"10.1016\/S0925-5710(96)00566-X"},{"key":"2019111704503707100_REF3","doi-asserted-by":"crossref","unstructured":"Maes B, Meeus P, Michaux L, et al. Application of the International Prognostic Scoring System for myelodysplastic syndromes. Ann Oncol. 1999;10: 825-829.","DOI":"10.1023\/A:1008335814674"},{"key":"2019111704503707100_REF4","unstructured":"Sanz GF, Sanz MA, Greenberg PL. Prognostic factors and scoring systems in myelodysplastic syndromes. Haematologica. 1998;83: 358-368."},{"key":"2019111704503707100_REF5","unstructured":"Jacobs JJ, van Lohuizen M. Polycomb repression: from cellular memory to cellular proliferation and cancer. Biochim Biophys Acta. 2002;1602: 151-161."},{"key":"2019111704503707100_REF6","doi-asserted-by":"crossref","unstructured":"Orlando V. Polycomb, epigenomes, and control of cell identity. Cell. 2003;112: 599-606.","DOI":"10.1016\/S0092-8674(03)00157-0"},{"key":"2019111704503707100_REF7","doi-asserted-by":"crossref","unstructured":"Park IK, Qian D, Kie M, et al. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature. 2003;423: 302-305.","DOI":"10.1038\/nature01587"},{"key":"2019111704503707100_REF8","doi-asserted-by":"crossref","unstructured":"Dick JE. Stem cells: self-renewal writ in blood. Nature. 2003;423: 231-233.","DOI":"10.1038\/423231a"},{"key":"2019111704503707100_REF9","doi-asserted-by":"crossref","unstructured":"Ohta H, Sawada A, Kim JY, et al. Polycomb group gene rae28 is required for sustaining activity of hematopoietic stem cells. J Exp Med. 2002;195: 759-770.","DOI":"10.1084\/jem.20011911"},{"key":"2019111704503707100_REF10","doi-asserted-by":"crossref","unstructured":"Lessard J, Sauvageau G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature. 2003;423: 231-233.","DOI":"10.1038\/nature01572"},{"key":"2019111704503707100_REF11","doi-asserted-by":"crossref","unstructured":"van der Lugt NM, Domen J, Linders K, et al. Posterior transformation, neurological abnormalities, and severe hematopoietic defects in mice with a targeted deletion of the bmi-1 proto-oncogene. Genes Dev. 1994;8: 757-769.","DOI":"10.1101\/gad.8.7.757"},{"key":"2019111704503707100_REF12","doi-asserted-by":"crossref","unstructured":"Iwama A, Oguro H, Negishi M, et al. Enhanced self-renewal of hematopoietic stem cells mediated by the polycomb gene product Bmi-1. Immunity. 2004;21: 843-851.","DOI":"10.1016\/j.immuni.2004.11.004"},{"key":"2019111704503707100_REF13","unstructured":"Dimri GP, Martinez JL, Jacobs JJ, et al. The Bmi-1 oncogene induces telomerase activity and immortalizes human mammary epithelial cells. Cancer Res. 2002;62: 4736-4745."},{"key":"2019111704503707100_REF14","doi-asserted-by":"crossref","unstructured":"Leung C, Lingbeek M, Shakhova O, et al. Bmi1 is essential for cerebellar development and is overexpressed in human medulloblastomas. Nature. 2004;428: 337-341.","DOI":"10.1038\/nature02385"},{"key":"2019111704503707100_REF15","doi-asserted-by":"crossref","unstructured":"Raaphorst FM, Meijer CJ, Fieret E, et al. Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene. Neoplasia. 2003;5: 481-488.","DOI":"10.1016\/S1476-5586(03)80032-5"},{"key":"2019111704503707100_REF16","doi-asserted-by":"crossref","unstructured":"Vonlanthen S, Heighway J, Altermatt HJ, et al. The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression. Br J Cancer. 2001; 84: 1372-1376.","DOI":"10.1054\/bjoc.2001.1791"},{"key":"2019111704503707100_REF17","unstructured":"Bea S, Tort F, Pinyol M, et al. BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas. Cancer Res. 2001;15: 2409-2412."},{"key":"2019111704503707100_REF18","doi-asserted-by":"crossref","unstructured":"Dukers DF, van Galen JC, Giroth C, et al. Unique polycomb gene expression pattern in Hodgkin's lymphoma and Hodgkin's lymphoma-derived cell lines. Am J Pathol. 2004;164: 873-881.","DOI":"10.1016\/S0002-9440(10)63175-6"},{"key":"2019111704503707100_REF19","doi-asserted-by":"crossref","unstructured":"van Kemenade FJ, Raaphorst FM, Blokzijl T, et al. Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. Blood. 2001;97: 3896-3901.","DOI":"10.1182\/blood.V97.12.3896"},{"key":"2019111704503707100_REF20","doi-asserted-by":"crossref","unstructured":"Zhang P, Iwasaki-Arai J, Iwasaki H, et al. Enhancement of hematopoietic stem cell repopulating capacity and self-renewal in the absence of the transcription factor C\/EBP alpha. Immunity. 2004;21: 853-863.","DOI":"10.1016\/j.immuni.2004.11.006"},{"key":"2019111704503707100_REF21","unstructured":"Takihara Y, Hara J. Polycomb-group genes and hematopoiesis. Int J Hematol. 2000;72: 165-172."},{"key":"2019111704503707100_REF22","doi-asserted-by":"crossref","unstructured":"Jacobs JJ, Kieboom K, Marino S, DePinho RA, van Lohuizen M. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature. 1999;397: 164-168.","DOI":"10.1038\/16476"},{"key":"2019111704503707100_REF23","doi-asserted-by":"crossref","unstructured":"Smith KS, Chanda SK, Lingbeek M, et al. Bmi-1 regulation of INK4A-ARF is a downstream requirement for transformation of hematopoietic progenitors by E2a-Pbx1. Mol Cell. 2003;12: 393-400.","DOI":"10.1016\/S1097-2765(03)00277-6"},{"key":"2019111704503707100_REF24","doi-asserted-by":"crossref","unstructured":"Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell. 1995;83: 993-1000.","DOI":"10.1016\/0092-8674(95)90214-7"},{"key":"2019111704503707100_REF25","doi-asserted-by":"crossref","unstructured":"Miller JS, McCullar V, Punzel M, Lemischka IR, Moore KA. Single adult human CD34(+)\/Lin-\/CD38(-) progenitors give rise to natural killer cells, B-lineage cells, dendritic cells, and myeloid cells. Blood. 1999;93: 96-106.","DOI":"10.1182\/blood.V93.1.96"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/107\/1\/305\/1279295\/zh800106000305.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/107\/1\/305\/1279295\/zh800106000305.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T09:50:50Z","timestamp":1573984250000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/107\/1\/305\/21743\/Bmi1-is-useful-as-a-novel-molecular-marker-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2005-06-2393","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,1,1]]}}}